# KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

> **NCT03915405** · PHASE1 · TERMINATED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** KHK2455
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03915405
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-26
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Termination was based on the business decision
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915405, "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03915405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*